{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:26Z","timestamp":1792783406256,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["No. 2025-I2M-XHCL-061"],"award-info":[{"award-number":["No. 2025-I2M-XHCL-061"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0510400"],"award-info":[{"award-number":["2023ZD0510400"]}]},{"name":"the Tianjin Municipal Science and Technology Commission Grant","award":["25ZXRKSY00040"],"award-info":[{"award-number":["25ZXRKSY00040"]}],"id":[{"id":"https:\/\/ror.org\/03wb1xh22","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Sciences Foundation of China","award":["82470208"],"award-info":[{"award-number":["82470208"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC2510500"],"award-info":[{"award-number":["2024YFC2510500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Research Fund for Clinical Application of Amphotericin B Antifungal Agents","award":["KC2024-JX-0092-1"],"award-info":[{"award-number":["KC2024-JX-0092-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"DOI":"10.1007\/s15010-026-02989-3","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:52:30Z","timestamp":1791363150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antifungal prophylaxis in patients with haematological malignancies receiving chemotherapy or haematopoietic stem cell transplantation: a systematic review and network meta-analysis"],"prefix":"10.1007","author":[{"given":"Ruonan","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2768-6690","authenticated-orcid":false,"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2989_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s44313-025-00113-2","volume":"60","author":"S-Y Cho","year":"2025","unstructured":"Cho S-Y, Lee CE, Nho D, Lee D-G. Invasive fungal infections in hematologic diseases: evidence, challenges, and clinical practice. Blood Res. 2025;60:65. https:\/\/doi.org\/10.1007\/s44313-025-00113-2.","journal-title":"Blood Res"},{"key":"2989_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101190","volume":"92","author":"R Sprute","year":"2023","unstructured":"Sprute R, Nacov JA, Neofytos D, Oliverio M, Prattes J, Reinhold I, et al. Antifungal prophylaxis and pre-emptive therapy: when and how? Mol Aspects Med. 2023;92:101190. https:\/\/doi.org\/10.1016\/j.mam.2023.101190.","journal-title":"Mol Aspects Med"},{"key":"2989_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","volume":"78","author":"J Stemler","year":"2022","unstructured":"Stemler J, Mellinghoff SC, Khodamoradi Y, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2022;78:1813\u201326. https:\/\/doi.org\/10.1093\/jac\/dkad143.","journal-title":"J Antimicrob Chemother"},{"key":"2989_CR4","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:3043\u201354. https:\/\/doi.org\/10.1200\/JCO.18.00374.","journal-title":"J Clin Oncol"},{"key":"2989_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","volume":"39","author":"L Pagano","year":"2025","unstructured":"Pagano L, Maschmeyer G, Lamoth F, et al. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2025;39:1547\u201357. https:\/\/doi.org\/10.1038\/s41375-025-02586-7.","journal-title":"Leukemia"},{"key":"2989_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102804","volume":"18","author":"M Popova","year":"2025","unstructured":"Popova M, Rogacheva Y. Epidemiology of invasive fungal diseases in patients with hematological malignancies and haematopoietic cell transplantation recipients: systematic review and meta-analysis of trends over time. J Infect Public Health. 2025;18:102804. https:\/\/doi.org\/10.1016\/j.jiph.2025.102804.","journal-title":"J Infect Public Health"},{"key":"2989_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/cid\/ciae612","volume":"80","author":"C Li","year":"2025","unstructured":"Li C, Zhu D-P, Chen J, Zhu X-Y, Li N-N, Cao W-J, et al. Invasive fungal disease in patients undergoing allogeneic hematopoietic stem cell transplantation in China: a multicenter epidemiological study (CAESAR 2.0). Clin Infect Dis. 2025;80:807\u201316. https:\/\/doi.org\/10.1093\/cid\/ciae612.","journal-title":"Clin Infect Dis"},{"key":"2989_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJM199203263261301","volume":"326","author":"JL Goodman","year":"1992","unstructured":"Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845\u201351. https:\/\/doi.org\/10.1056\/NEJM199203263261301.","journal-title":"N Engl J Med"},{"key":"2989_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348\u201359. https:\/\/doi.org\/10.1056\/NEJMoa061094.","journal-title":"N Engl J Med"},{"key":"2989_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/422312","volume":"39","author":"JAH Van Burik","year":"2004","unstructured":"Van Burik JAH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407\u201316. https:\/\/doi.org\/10.1086\/422312.","journal-title":"Clin Infect Dis"},{"key":"2989_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa061098.","journal-title":"N Engl J Med"},{"issue":"10","key":"2989_CR12","doi-asserted-by":"publisher","first-page":"e2017652","DOI":"10.1001\/jamanetworkopen.2020.17652","volume":"3","author":"J Wang","year":"2020","unstructured":"Wang J, Zhou M, Xu JY, Zhou RF, Chen B, Wan Y. Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: a systematic review and network meta-analysis. JAMA Netw Open. 2020;3:e2017652. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.17652.","journal-title":"JAMA Netw Open"},{"key":"2989_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-18","volume":"62","author":"CH Lee","year":"2018","unstructured":"Lee CH, Lin C, Ho CL, Lin JC. Primary fungal prophylaxis in hematological malignancy: a network meta-analysis of randomized controlled trials. Antimicrob Agents Chemother. 2018;62:e00355-18. https:\/\/doi.org\/10.1128\/AAC.00355-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"2989_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/cid\/ciae203","volume":"79","author":"CA Boutin","year":"2024","unstructured":"Boutin CA, Durocher F, Beauchemin S, Ziegler D, Abou Chakra CN, Dufresne SF. Breakthrough invasive fungal infections in patients with high-risk hematological disorders receiving voriconazole and posaconazole prophylaxis: a systematic review. Clin Infect Dis. 2024;79:151\u201360. https:\/\/doi.org\/10.1093\/cid\/ciae203.","journal-title":"Clin Infect Dis"},{"key":"2989_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","volume":"80","author":"L Chen","year":"2020","unstructured":"Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Br\u00fcggemann RJM. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020;80:671\u201395. https:\/\/doi.org\/10.1007\/s40265-020-01306-y.","journal-title":"Drugs"},{"key":"2989_CR16","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1128\/AAC.00581-15","volume":"59","author":"A Cumpston","year":"2015","unstructured":"Cumpston A, Caddell R, Shillingburg A, et al. Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies. Antimicrob Agents Chemother. 2015;59:4424\u20138. https:\/\/doi.org\/10.1128\/AAC.00581-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"2989_CR17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1128\/AAC.01034-08","volume":"53","author":"G Krishna","year":"2009","unstructured":"Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958\u201366. https:\/\/doi.org\/10.1128\/AAC.01034-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"2989_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02655-17","volume":"62","author":"D Lenczuk","year":"2018","unstructured":"Lenczuk D, Zinke-Cerwenka W, Greinix H, W\u00f6lfler A, Prattes J, Zollner-Schwetz I, et al. Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy, and tolerability. Antimicrob Agents Chemother. 2018;62:e02655-17. https:\/\/doi.org\/10.1128\/aac.02655-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"2989_CR19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/cid\/ciz282","volume":"70","author":"L Fontana","year":"2020","unstructured":"Fontana L, Perlin DS, Zhao Y, Noble BN, Lewis JS, Strasfeld L, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020;70:723\u201330. https:\/\/doi.org\/10.1093\/cid\/ciz282.","journal-title":"Clin Infect Dis"},{"key":"2989_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/16078454.2022.2076046","volume":"27","author":"Y Ping","year":"2022","unstructured":"Ping Y, Hongmei J, Bellmann C, et al. Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting. Hematology Am Soc Hematol Educ Program. 2022;27:723\u201332. https:\/\/doi.org\/10.1080\/16078454.2022.2076046.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2989_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf163","volume":"12","author":"K Ishida","year":"2025","unstructured":"Ishida K, Haraguchi M, Kimura M, Araoka H, Natori A, Reynolds JM, et al. Incidence of breakthrough fungal infections in patients with isavuconazole prophylaxis: a systematic review and meta-analysis. Open Forum Infect Dis. 2025;12:ofaf163. https:\/\/doi.org\/10.1093\/ofid\/ofaf163.","journal-title":"Open Forum Infect Dis"},{"key":"2989_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"2989_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2989_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jiac.2017.02.011","volume":"23","author":"X Xu","year":"2017","unstructured":"Xu X, Zhang L, Cao X, Li J, Zhang W, Zhu T, et al. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China. J Infect Chemother. 2017;23:360\u20137. https:\/\/doi.org\/10.1016\/j.jiac.2017.02.011.","journal-title":"J Infect Chemother"},{"key":"2989_CR25","unstructured":"Plummer M. JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. In Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003) [Internet]. Vienna, Austria; 2003. https:\/\/www.r-project.org\/conferences\/DSC-2003\/Proceedings\/Plummer.pdf"},{"key":"2989_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G Van Valkenhoef","year":"2012","unstructured":"Van Valkenhoef G, Lu G, De Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synthesis Methods. 2012;3:285\u201399. https:\/\/doi.org\/10.1002\/jrsm.1054.","journal-title":"Res Synthesis Methods"},{"key":"2989_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s12185-008-0196-y","volume":"88","author":"Y Hiramatsu","year":"2008","unstructured":"Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol. 2008;88:588\u201395. https:\/\/doi.org\/10.1007\/s12185-008-0196-y.","journal-title":"Int J Hematol"},{"key":"2989_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/jac\/dki440","volume":"57","author":"A Glasmacher","year":"2006","unstructured":"Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother. 2006;57:317\u201325. https:\/\/doi.org\/10.1093\/jac\/dki440.","journal-title":"J Antimicrob Chemother"},{"key":"2989_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-026-04252-9","author":"Y Hayashi","year":"2026","unstructured":"Hayashi Y, Kanda Y, Nakamae H, Tanaka M, Doki N, Hidaka M, et al. Voriconazole versus itraconazole for antifungal prophylaxis in patients with graft-versus-host disease: a prospective randomized trial. Int J Hematol. 2026. https:\/\/doi.org\/10.1007\/s12185-026-04252-9.","journal-title":"Int J Hematol"},{"key":"2989_CR30","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.bbmt.2012.03.014","volume":"18","author":"X Huang","year":"2012","unstructured":"Huang X, Chen H, Han M, et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transpl. 2012;18:1509\u201316. https:\/\/doi.org\/10.1016\/j.bbmt.2012.03.014.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2989_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","volume":"103","author":"KA Marr","year":"2004","unstructured":"Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527\u201333. https:\/\/doi.org\/10.1182\/blood-2003-08-2644.","journal-title":"Blood"},{"key":"2989_CR32","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood.V110.11.1824.1824","volume":"110","author":"G Mattiuzzi","year":"2007","unstructured":"Mattiuzzi G, Cortes J, Blamble D, Estey E, Kantarjian H. Liposomal amphotericin B IV (LIPO AB) once per week is effective in the prevention of invasive fungal infections (IFI) in patients (pts) with acute leukemia: preliminary analysis of a randomized trial. Blood. 2007;110:1824\u20131824. https:\/\/doi.org\/10.1182\/blood.V110.11.1824.1824.","journal-title":"Blood"},{"key":"2989_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1128\/AAC.50.1.143-147.2006","volume":"50","author":"GN Mattiuzzi","year":"2006","unstructured":"Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50:143\u20137. https:\/\/doi.org\/10.1128\/AAC.50.1.143-147.2006.","journal-title":"Antimicrob Agents Chemother"},{"key":"2989_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00520-009-0783-3","volume":"19","author":"GN Mattiuzzi","year":"2011","unstructured":"Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011;19:19\u201326. https:\/\/doi.org\/10.1007\/s00520-009-0783-3.","journal-title":"Support Care Cancer"},{"key":"2989_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/sj.bmt.1705418","volume":"38","author":"I Oren","year":"2006","unstructured":"Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006;38:127\u201334. https:\/\/doi.org\/10.1038\/sj.bmt.1705418.","journal-title":"Bone Marrow Transplant"},{"key":"2989_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jinf.2016.06.011","volume":"73","author":"S Park","year":"2016","unstructured":"Park S, Kim K, Jang JH, et al. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Infect. 2016;73:496\u2013505. https:\/\/doi.org\/10.1016\/j.jinf.2016.06.011.","journal-title":"J Infect"},{"key":"2989_CR37","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","volume":"17","author":"O Penack","year":"2006","unstructured":"Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol. 2006;17:1306\u201312. https:\/\/doi.org\/10.1093\/annonc\/mdl128.","journal-title":"Ann Oncol"},{"key":"2989_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","volume":"138","author":"DJ Winston","year":"2003","unstructured":"Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med. 2003;138:705\u201313. https:\/\/doi.org\/10.7326\/0003-4819-138-9-200305060-00006.","journal-title":"Ann Intern Med"},{"key":"2989_CR39","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1093\/jac\/dkr271","volume":"66","author":"C Cattaneo","year":"2011","unstructured":"Cattaneo C, Monte S, Algarotti A, et al. A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). J Antimicrob Chemother. 2011;66:2140\u20135. https:\/\/doi.org\/10.1093\/jac\/dkr271.","journal-title":"J Antimicrob Chemother"},{"key":"2989_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/TP.0b013e3182577485","volume":"94","author":"A-M Chaftari","year":"2012","unstructured":"Chaftari A-M, Hachem RY, Ramos E, Kassis C, Campo M, Jiang Y, et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation. 2012;94:302\u20138. https:\/\/doi.org\/10.1097\/TP.0b013e3182577485.","journal-title":"Transplantation"},{"key":"2989_CR41","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1093\/jac\/dkx133","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely OA, Leguay T, Maertens J, Vehreschild MJGT, Anagnostopoulos A, Castagnola C, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017;72:2359\u201367. https:\/\/doi.org\/10.1093\/jac\/dkx133.","journal-title":"J Antimicrob Chemother"},{"key":"2989_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","volume":"77","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Seo SK, Huang Y-T, Park JH, Klimek VM, Berman E, et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study. J Infect. 2018;77:227\u201334. https:\/\/doi.org\/10.1016\/j.jinf.2018.03.015.","journal-title":"J Infect"},{"key":"2989_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1532\/IJH97.06079","volume":"85","author":"Y Ito","year":"2007","unstructured":"Ito Y, Ohyashiki K, Yoshida I, Takeuchi M, Aoyama Y, Mugitani A, et al. The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a japanese multicenter randomized, controlled study. Int J Hematol. 2007;85:121\u20137. https:\/\/doi.org\/10.1532\/IJH97.06079.","journal-title":"Int J Hematol"},{"key":"2989_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","volume":"155","author":"DI Marks","year":"2011","unstructured":"Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318\u201327. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08838.x.","journal-title":"Br J Haematol"},{"key":"2989_CR45","doi-asserted-by":"publisher","first-page":"738","DOI":"10.5414\/CP201880","volume":"51","author":"Y Shen","year":"2013","unstructured":"Shen Y, Huang XJ, Wang JX, et al. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. Int J Clin Pharmacol Ther. 2013;51:738\u201345. https:\/\/doi.org\/10.5414\/CP201880.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2989_CR46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jinf.2007.07.003","volume":"55","author":"JJ Vehreschild","year":"2007","unstructured":"Vehreschild JJ, B\u00f6hme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect. 2007;55:445\u20139. https:\/\/doi.org\/10.1016\/j.jinf.2007.07.003.","journal-title":"J Infect"},{"key":"2989_CR47","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","volume":"116","author":"JR Wingard","year":"2010","unstructured":"Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111\u20138. https:\/\/doi.org\/10.1182\/blood-2010-02-268151.","journal-title":"Blood"},{"key":"2989_CR48","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s12288-020-01259-y","volume":"36","author":"AMS El-Ghammaz","year":"2020","unstructured":"El-Ghammaz AMS, El-Zimaity M, Elafifi AM, et al. Effectiveness and cost-effectiveness of prophylactic voriconazole and fluconazole regarding prevention of post-hematopoietic stem cell transplantation invasive fungal infection and its related death: a single center experience. Indian J Hematol Blood Transfus. 2020;36:680\u20139. https:\/\/doi.org\/10.1007\/s12288-020-01259-y.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2989_CR49","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/jac\/dkq121","volume":"65","author":"JJ Vehreschild","year":"2010","unstructured":"Vehreschild JJ, Ruping MJGT, Wisplinghoff H, Farowski F, Steinbach A, Sims R, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65:1466\u201371. https:\/\/doi.org\/10.1093\/jac\/dkq121.","journal-title":"J Antimicrob Chemother"},{"key":"2989_CR50","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.cmi.2024.07.019","volume":"30","author":"J Cao","year":"2024","unstructured":"Cao J, Pan P, Feng D, Wang M, Zheng Y, Yang N, et al. Posaconazole gastro-resistant tablets for preventing invasive fungal disease after haematopoietic stem cell transplantation: a propensity-matched cohort study. Clin Microbiol Infect. 2024;30:1585\u201391. https:\/\/doi.org\/10.1016\/j.cmi.2024.07.019.","journal-title":"Clin Microbiol Infect"},{"key":"2989_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0305-y","volume":"9","author":"L Gao","year":"2016","unstructured":"Gao L, Sun Y, Meng F, et al. Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study. J Hematol Oncol. 2016;9:97. https:\/\/doi.org\/10.1186\/s13045-016-0305-y.","journal-title":"J Hematol Oncol"},{"key":"2989_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12288-019-01173-y","volume":"36","author":"B George","year":"2020","unstructured":"George B, Menon H, Bhurani D, Damodar S, Apte S, Seth T, et al. Indian J Hematol Blood Transfus. 2020;36:97\u2013103. https:\/\/doi.org\/10.1007\/s12288-019-01173-y.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2989_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12185-007-0011-1","volume":"87","author":"S Hashino","year":"2008","unstructured":"Hashino S, Morita L, Takahata M, Onozawa M, Nakagawa M, Kawamura T, et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol. 2008;87:91\u20137. https:\/\/doi.org\/10.1007\/s12185-007-0011-1.","journal-title":"Int J Hematol"},{"key":"2989_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12288-024-01790-2","volume":"41","author":"G Metan","year":"2025","unstructured":"Metan G, \u00c7ift\u00e7ioglu A, Saba R, et al. Antifungal prophylaxis and treatment of breakthrough invasive fungal diseases in high-risk hematology patients: a prospective observational multicenter study. INDIAN J Hematol BLOOD Transfus. 2025;41:75\u201388. https:\/\/doi.org\/10.1007\/s12288-024-01790-2.","journal-title":"INDIAN J Hematol BLOOD Transfus"},{"key":"2989_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clml.2021.10.011","volume":"22","author":"M Michallet","year":"2022","unstructured":"Michallet M, Sobh M, Morisset S, Deloire A, Raffoux E, de Botton S, et al. Antifungal prophylaxis in AML patients receiving intensive induction chemotherapy: a prospective observational study from the acute leukaemia french association (ALFA) group. Clin Lymphoma Myeloma Leuk. 2022;22:311\u20138. https:\/\/doi.org\/10.1016\/j.clml.2021.10.011.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2989_CR56","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1093\/cid\/cis773","volume":"55","author":"L Pagano","year":"2010","unstructured":"Pagano L, Caira M, Candoni A, Aversa F, Castagnola C, Caramatti C, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis. 2010;55:1515\u201321. https:\/\/doi.org\/10.1093\/cid\/cis773.","journal-title":"Clin Infect Dis"},{"key":"2989_CR57","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.21037\/tcr-19-2887","volume":"9","author":"Y Sun","year":"2020","unstructured":"Sun Y, Hu J, Huang H, Chen J, Li J, Ma J, et al. Fluconazole is as effective as other anti-mold agents in preventing early invasive fungal disease after allogeneic stem cell transplantation: assessment of antifungal therapy in haematological disease in China. Transl Cancer Res. 2020;9:6900\u201311. https:\/\/doi.org\/10.21037\/tcr-19-2887.","journal-title":"Transl Cancer Res"},{"key":"2989_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14207294","volume":"14","author":"U Atas","year":"2025","unstructured":"Atas U, Iltar U, Yucel OK, Salur H, Bilek MC, Ustabas T, et al. Real-world outcomes of antifungal prophylaxis in adult acute lymphoblastic leukemia patients: a multicenter comparison of the use of fluconazole and micafungin. J Clin Med. 2025;14:7294. https:\/\/doi.org\/10.3390\/jcm14207294.","journal-title":"J Clin Med"},{"key":"2989_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105886","volume":"55","author":"MS Copley","year":"2020","unstructured":"Copley MS, Waldron M, Athans V, et al. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: a retrospective study. Int J Antimicrob Agents. 2020;55:105886. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105886.","journal-title":"Int J Antimicrob Agents"},{"key":"2989_CR60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3138\/jammi-2022-0027","volume":"8","author":"SF Dufresne","year":"2023","unstructured":"Dufresne SF, Bergeron J, Beauchemin S, et al. Real-life comparison of posaconazole versus fluconazole for primary antifungal prophylaxis during remission-induction chemotherapy for acute leukemia. J Assoc Med Microbiol Infect Dis Can. 2023;8:18\u201328. https:\/\/doi.org\/10.3138\/jammi-2022-0027.","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"2989_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132184","author":"F Grimaldi","year":"2025","unstructured":"Grimaldi F, Memoli M, Avilia S, et al. Caspofungin for primary antifungal prophylaxis in acute myeloid leukemia: a real-life study from an academic center. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17132184.","journal-title":"Cancers (Basel)"},{"key":"2989_CR62","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.clinthera.2015.06.014","volume":"37","author":"S-Y Cho","year":"2015","unstructured":"Cho S-Y, Lee D-G, Choi J-K, Lee H-J, Kim S-H, Park S-H, et al. Cost-benefit analysis of posaconazole versus fluconazole or itraconazole as a primary antifungal prophylaxis in high-risk hematologic patients: a propensity score-matched analysis. Clin Ther. 2015;37:2019\u201327. https:\/\/doi.org\/10.1016\/j.clinthera.2015.06.014.","journal-title":"Clin Ther"},{"key":"2989_CR63","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/cid\/ciac230","volume":"75","author":"CR Rausch","year":"2022","unstructured":"Rausch CR, DiPippo AJ, Jiang Y, DiNardo CD, Kadia T, Maiti A, et al. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. Clin Infect Dis. 2022;75:1503\u201310. https:\/\/doi.org\/10.1093\/cid\/ciac230.","journal-title":"Clin Infect Dis"},{"key":"2989_CR64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12185-017-2342-x","volume":"107","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xing Y, Chen L, Meng T, Li Y, Xie J, et al. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis. Int J Hematol. 2018;107:235\u201343. https:\/\/doi.org\/10.1007\/s12185-017-2342-x.","journal-title":"Int J Hematol"},{"key":"2989_CR65","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/10781552231175825","volume":"30","author":"O White","year":"2024","unstructured":"White O, Kennedy E, Huckabee JB, Rogers E, LeBlanc TW, Dillon M, et al. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia. J Oncol Pharm Pract. 2024;30:527\u201334. https:\/\/doi.org\/10.1177\/10781552231175825.","journal-title":"J Oncol Pharm Pract"},{"key":"2989_CR66","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12288-018-0916-2","volume":"34","author":"D Bansal","year":"2018","unstructured":"Bansal D, Seth T, Kumar R, Saxena R, Mishra P, Xess I. Efficacy of posaconazole prophylaxis in patients with acute myeloid leukemia undergoing induction chemotherapy: an observational study in resource limited settings. Indian J Hematol Blood Transfus. 2018;34:460\u20135. https:\/\/doi.org\/10.1007\/s12288-018-0916-2.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2989_CR67","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/mmy\/myab025","volume":"59","author":"Y Bogler","year":"2021","unstructured":"Bogler Y, Stern A, Su Y, et al. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021;59:970\u20139. https:\/\/doi.org\/10.1093\/mmy\/myab025.","journal-title":"Med Mycol"},{"key":"2989_CR68","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00277-014-2259-x","volume":"94","author":"E Brissot","year":"2015","unstructured":"Brissot E, Cahu X, Guillaume T, et al. Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic\/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Ann Hematol. 2015;94:663\u20139. https:\/\/doi.org\/10.1007\/s00277-014-2259-x.","journal-title":"Ann Hematol"},{"key":"2989_CR69","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/1078155219876683","volume":"26","author":"V Bui","year":"2020","unstructured":"Bui V, Walker SA, Elligsen M, Vyas A, Kiss A, Palmay L. Voriconazole prophylaxis in leukemic patients: a retrospective single-center study. J Oncol Pharm Pract. 2020;26:873\u201381. https:\/\/doi.org\/10.1177\/1078155219876683.","journal-title":"J Oncol Pharm Pract"},{"key":"2989_CR70","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2009.012633","volume":"95","author":"A Chabrol","year":"2010","unstructured":"Chabrol A, Cuzin L, Huguet F, Alvarez M, Verdeil X, Linas MD, et al. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica. 2010;95:996\u20131003. https:\/\/doi.org\/10.3324\/haematol.2009.012633.","journal-title":"Haematologica"},{"key":"2989_CR71","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","volume":"63","author":"EC Chen","year":"2022","unstructured":"Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, et al. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022;63:1934\u201341. https:\/\/doi.org\/10.1080\/10428194.2022.2047964.","journal-title":"Leuk Lymphoma"},{"key":"2989_CR72","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720965846","volume":"11","author":"TC Chen","year":"2020","unstructured":"Chen TC, Wang RC, Lin YH, Chang KH, Hung LY, Teng CLJ. Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: is it still useful outside the clinical trial setting? Ther Adv Hematol. 2020;11:2040620720965846. https:\/\/doi.org\/10.1177\/2040620720965846.","journal-title":"Ther Adv Hematol"},{"key":"2989_CR73","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/ejh.12565","volume":"96","author":"T Dahl\u00e9n","year":"2016","unstructured":"Dahl\u00e9n T, Kalin M, Cederlund K, et al. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia\/myelodysplastic syndromes. Eur J Haematol. 2016;96:175\u201380. https:\/\/doi.org\/10.1111\/ejh.12565.","journal-title":"Eur J Haematol"},{"key":"2989_CR74","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jac\/dky550","volume":"74","author":"MI Del Principe","year":"2019","unstructured":"Del Principe MI, Dragonetti G, Verga L, et al. real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: sorveglianza epidemiologica infezioni nelle emopatie (SEIFEM) 2016 study. J Antimicrob Chemother. 2019;74:1062\u20138. https:\/\/doi.org\/10.1093\/jac\/dky550.","journal-title":"J Antimicrob Chemother"},{"key":"2989_CR75","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4103\/2319-4170.143491","volume":"38","author":"A Falk","year":"2015","unstructured":"Falk A, Raberin H, Menguy S, Guyotat D, Magn\u00e9 N, Cornillon J, et al. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia. Biomedical J. 2015;38:235. https:\/\/doi.org\/10.4103\/2319-4170.143491.","journal-title":"Biomedical J"},{"key":"2989_CR76","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2015.048","volume":"7","author":"J Elcheikh","year":"2015","unstructured":"Elcheikh J. Comparison of three distinct prophylactic agents against invasive fungal infections in patients undergoing haplo-identical hematopoietic stem cell transplantation and post-transplant cyclophosphamide. Mediterr J Hematol Infect Dis. 2015;7:e2015048. https:\/\/doi.org\/10.4084\/MJHID.2015.048.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2989_CR77","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5144\/1658-3876.2010.167","volume":"3","author":"JE Cheikh","year":"2010","unstructured":"Cheikh JE, Castagna L, Wang L, Esterni B, Faucher C, Furst S, et al. Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2010;3:167\u201373. https:\/\/doi.org\/10.5144\/1658-3876.2010.167.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2989_CR78","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/bmt.2009.210","volume":"45","author":"U Gergis","year":"2010","unstructured":"Gergis U, Markey K, Greene J, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010;45:662\u20137. https:\/\/doi.org\/10.1038\/bmt.2009.210.","journal-title":"Bone Marrow Transplant"},{"key":"2989_CR79","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3324\/haematol.2011.053058","volume":"97","author":"C Girmenia","year":"2012","unstructured":"Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S, et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica. 2012;97:560\u20137. https:\/\/doi.org\/10.3324\/haematol.2011.053058.","journal-title":"Haematologica"},{"key":"2989_CR80","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","volume":"50","author":"R Hachem","year":"2017","unstructured":"Hachem R, Assaf A, Numan Y, Shah P, Jiang Y, Chaftari A-M, et al. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Int J Antimicrob Agents. 2017;50:384\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.021.","journal-title":"Int J Antimicrob Agents"},{"key":"2989_CR81","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1439-0507.2010.01980.x","volume":"54","author":"J Hahn","year":"2011","unstructured":"Hahn J, Stifel F, Reichle A, Holler E, Andreesen R. Clinical experience with posaconazole prophylaxis \u2013 a retrospective analysis in a haematological unit. Mycoses. 2011;54:12\u20136. https:\/\/doi.org\/10.1111\/j.1439-0507.2010.01980.x.","journal-title":"Mycoses"},{"key":"2989_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12185-025-04059-0","volume":"123","author":"Y Hanyu","year":"2026","unstructured":"Hanyu Y, Kanda J, Sugimoto M, et al. Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2026;123:63\u201374. https:\/\/doi.org\/10.1007\/s12185-025-04059-0.","journal-title":"Int J Hematol"},{"key":"2989_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.108144","volume":"160","author":"CJ Hunter","year":"2026","unstructured":"Hunter CJ, Chou A, Roeder H, et al. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia. Leuk Res. 2026;160:108144. https:\/\/doi.org\/10.1016\/j.leukres.2025.108144.","journal-title":"Leuk Res"},{"key":"2989_CR84","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966882","author":"K Kang","year":"2020","unstructured":"Kang K, Lee B, Jeon M, et al. Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. Ther Adv Hematol. 2020. https:\/\/doi.org\/10.1177\/2040620720966882.","journal-title":"Ther Adv Hematol"},{"key":"2989_CR85","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/cam4.225","volume":"3","author":"H Kung","year":"2014","unstructured":"Kung H, Johnson MD, Drew RH, Saha-Chaudhuri P, Perfect JR. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology\u2013oncology patients: a retrospective cohort study. Cancer Med. 2014;3:667\u201373. https:\/\/doi.org\/10.1002\/cam4.225.","journal-title":"Cancer Med"},{"key":"2989_CR86","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41409-025-02589-z","volume":"60","author":"V Letailleur","year":"2025","unstructured":"Letailleur V, Jullien M, Garnier A, Peterlin P, Vantyghem S, Fourmont A-M, et al. Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2025;60:1092\u2013101. https:\/\/doi.org\/10.1038\/s41409-025-02589-z.","journal-title":"Bone Marrow Transplant"},{"key":"2989_CR87","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/1078155214560920","volume":"22","author":"H Luu Tran","year":"2016","unstructured":"Luu Tran H, Mahmoudjafari Z, Rockey M, et al. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. J Oncol Pharm Pract. 2016;22:228\u201334. https:\/\/doi.org\/10.1177\/1078155214560920.","journal-title":"J Oncol Pharm Pract"},{"key":"2989_CR88","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/cncr.11936","volume":"100","author":"GN Mattiuzzi","year":"2004","unstructured":"Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100:581\u20139. https:\/\/doi.org\/10.1002\/cncr.11936.","journal-title":"Cancer"},{"key":"2989_CR89","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12288-014-0472-3","volume":"31","author":"G Metan","year":"2015","unstructured":"Metan G, T\u00fcre Z, Pala \u00c7, Kaynar L, Y\u0131ld\u0131r\u0131m A, Elmal\u0131 F, et al. A single center experience for antifungal prophylaxis in patients with acute myelogenous leukemia. Indian J Hematol Blood Transfus. 2015;31:339\u201345. https:\/\/doi.org\/10.1007\/s12288-014-0472-3.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2989_CR90","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2011.557668","author":"M Michallet","year":"2011","unstructured":"Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini F-E, Thomas X, et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol. 2011. https:\/\/doi.org\/10.3109\/13693786.2011.557668.","journal-title":"Med Mycol"},{"key":"2989_CR91","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/bmt.2015.181","volume":"50","author":"P Montesinos","year":"2015","unstructured":"Montesinos P, Rodr\u00edguez-Veiga R, Boluda B, Mart\u00ednez-Cuadr\u00f3n D, Cano I, Lancharro A, et al. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. Bone Marrow Transplant. 2015;50:1465\u201372. https:\/\/doi.org\/10.1038\/bmt.2015.181.","journal-title":"Bone Marrow Transplant"},{"key":"2989_CR92","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/ejh.12426","volume":"94","author":"D Nachbaur","year":"2015","unstructured":"Nachbaur D, Angelova O, Orth-H\u00f6ller D, Ditlbacher A, Lackner M, Auberger J, et al. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real\u2010life data from a retrospective single\u2010centre observational study. Eur J Haematol. 2015;94:258\u201364. https:\/\/doi.org\/10.1111\/ejh.12426.","journal-title":"Eur J Haematol"},{"key":"2989_CR93","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3760\/cma.j.issn.0253-2727.2014.07.001","volume":"35","author":"Z Qiu","year":"2014","unstructured":"Qiu Z, Ren H, Cen X, et al. Clinical investigation of reduced-dose voriconazole on primary prevention in invasive fungal disease after allogeneic hematopoietic stem cell transplantation. Zhonghua xue ye xue za zhi. 2014;35:577\u201380. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2014.07.001.","journal-title":"Zhonghua xue ye xue za zhi"},{"key":"2989_CR94","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00277-019-03744-5","volume":"98","author":"R Rodr\u00edguez-Veiga","year":"2019","unstructured":"Rodr\u00edguez-Veiga R, Montesinos P, Boluda B, Lorenzo I, Mart\u00ednez-Cuadr\u00f3n D, Salavert M, et al. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Ann Hematol. 2019;98:2081\u20138. https:\/\/doi.org\/10.1007\/s00277-019-03744-5.","journal-title":"Ann Hematol"},{"key":"2989_CR95","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14045","volume":"25","author":"SA Scott","year":"2023","unstructured":"Scott SA, Perry C, Mahmoudjafari Z, Martin GA, Boyd S, Thompson J, et al. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole. Transplant Infect Dis. 2023;25:e14045. https:\/\/doi.org\/10.1111\/tid.14045.","journal-title":"Transplant Infect Dis"},{"key":"2989_CR96","doi-asserted-by":"publisher","first-page":"e883","DOI":"10.1016\/j.clml.2020.06.008","volume":"20","author":"J Signorelli","year":"2020","unstructured":"Signorelli J, Lei M, Lam J, Jalbut M, Amrein PC, Fathi AT, et al. Incidence of invasive fungal infections in acute myeloid leukemia without antifungal prophylaxis. Clin Lymphoma Myeloma Leuk. 2020;20:e883\u20139. https:\/\/doi.org\/10.1016\/j.clml.2020.06.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2989_CR97","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.mycmed.2017.11.003","volume":"28","author":"L Tang","year":"2018","unstructured":"Tang L, Yang X-F, Qiao M, Zhang L, Tang X-W, Qiu H-Y, et al. Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: a retrospective study. J Mycol Med. 2018;28:379\u201383. https:\/\/doi.org\/10.1016\/j.mycmed.2017.11.003.","journal-title":"J Mycol Med"},{"key":"2989_CR98","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1177\/10781552231212204","volume":"30","author":"N Teran","year":"2024","unstructured":"Teran N, Park G. Optimizing antimicrobial prophylaxis strategies in acute leukemia patients: assessing the efficacy of fluconazole. J Oncol Pharm Pract. 2024;30:1330\u20134. https:\/\/doi.org\/10.1177\/10781552231212204.","journal-title":"J Oncol Pharm Pract"},{"key":"2989_CR99","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/myc.12728","volume":"61","author":"M Tormo","year":"2018","unstructured":"Tormo M, P\u00e9rez-Mart\u00ednez A, Calabuig M, Hern\u00e1ndez\u2010Boluda JC, Amat P, Navarro D, et al. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high\u2010risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: a real\u2010world comparison. Mycoses. 2018;61:206\u201312. https:\/\/doi.org\/10.1111\/myc.12728.","journal-title":"Mycoses"},{"key":"2989_CR100","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jmii.2014.07.009","volume":"49","author":"CH Wang","year":"2016","unstructured":"Wang CH, Kan LP, Lin HA, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients\u2014a retrospective analysis of a single medical center in Taiwan. J Microbiol Immunol Infect. 2016;49:531\u20138. https:\/\/doi.org\/10.1016\/j.jmii.2014.07.009.","journal-title":"J Microbiol Immunol Infect"},{"key":"2989_CR101","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025448","volume":"100","author":"E Yang","year":"2021","unstructured":"Yang E, Choi EJ, Park HS, et al. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: a single-center, observational, case-control study in South Korea. Medicine (Baltimore). 2021;100:e25448. https:\/\/doi.org\/10.1097\/MD.0000000000025448.","journal-title":"Medicine (Baltimore)"},{"key":"2989_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102593","volume":"91","author":"LR Soldi","year":"2024","unstructured":"Soldi LR, Silva MJB. Fluconazole and levofloxacin prophylaxis are ineffective strategies for preventing infections in acute myeloid leukemia patients undergoing chemotherapy. Cancer Epidemiol. 2024;91:102593. https:\/\/doi.org\/10.1016\/j.canep.2024.102593.","journal-title":"Cancer Epidemiol"},{"key":"2989_CR103","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/bmt.2010.185","volume":"46","author":"I S\u00e1nchez-Ortega","year":"2011","unstructured":"S\u00e1nchez-Ortega I, Pati\u00f1o B, Arnan M, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2011;46:733\u20139. https:\/\/doi.org\/10.1038\/bmt.2010.185.","journal-title":"Bone Marrow Transplant"},{"key":"2989_CR104","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00893-18","volume":"62","author":"JP Furuno","year":"2018","unstructured":"Furuno JP, Tallman GB, Noble BN, Bubalo JS, Forrest GN, Lewis JS, et al. Clinical outcomes of oral suspension versus delayed-release tablet formulations of posaconazole for prophylaxis of invasive fungal infections. Antimicrob Agents Chemother. 2018;62:e00893-18. https:\/\/doi.org\/10.1128\/AAC.00893-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"2989_CR105","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3760\/cma.j.issn.0253-2727.2023.02.002","volume":"44","author":"Medical Mycology Society of Chinese Medicine and Education Association; Chinese Society of Hematology, Chinese Medical Association","year":"2023","unstructured":"Medical Mycology Society of Chinese Medicine and Education Association; Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus for invasive fungal disease in patients after hematopoietic stem cell transplantation (2023). Zhonghua Xue Ye Xue Za Zhi. 2023;44:92\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.02.002.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2989_CR106","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cpt.620","volume":"101","author":"J Keirns","year":"2017","unstructured":"Keirns J, Desai A, Kowalski D, et al. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther. 2017;101:782\u201390. https:\/\/doi.org\/10.1002\/cpt.620.","journal-title":"Clin Pharmacol Ther"},{"key":"2989_CR107","doi-asserted-by":"publisher","first-page":"O952","DOI":"10.1111\/1469-0691.12688","volume":"20","author":"N Lerolle","year":"2014","unstructured":"Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R, et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014;20:O952-9. https:\/\/doi.org\/10.1111\/1469-0691.12688.","journal-title":"Clin Microbiol Infect"},{"key":"2989_CR108","doi-asserted-by":"publisher","DOI":"10.1111\/myc.70123","volume":"68","author":"C Marchetti","year":"2025","unstructured":"Marchetti C, Glampedakis E, Stemler J, H\u00e4nsel L, Kuster S, Kronig I, et al. Breakthrough invasive mould infections under posaconazole prophylaxis in patients with haematologic malignancies: a case\u2013control study. Mycoses. 2025;68:e70123. https:\/\/doi.org\/10.1111\/myc.70123.","journal-title":"Mycoses"},{"key":"2989_CR109","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1093\/cid\/cix130","volume":"64","author":"F Lamoth","year":"2017","unstructured":"Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis. 2017;64:1619\u201321. https:\/\/doi.org\/10.1093\/cid\/cix130.","journal-title":"Clin Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02989-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:52:35Z","timestamp":1791363155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02989-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":109,"alternative-id":["2989"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02989-3","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ruonan Shao, Xinyi Li, Yuqing Cui, Xiaomeng Feng, Kanchao Chen, Qingxiang Huang, Yuping Fan, Xiaolei Pei, Xin Chen, and Sizhou Feng declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article analyses previously published studies and reports no new research involving human participants or animals.","order":2,"name":"Ethics","label":"<b>Ethical approval<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this study used previously published aggregate data and reports.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}